知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.015 秒)

    B.sub.2 adrenegic agonists and use thereof in the treatment of glaucoma
    1.
    发明授权
    B.sub.2 adrenegic agonists and use thereof in the treatment of glaucoma 失效
    B2 adrengic激动剂及其在治疗青光眼中的用途

    公开(公告)号：US5314916A

    公开(公告)日：1994-05-24

    申请号：US49462

    申请日：1993-04-19

    申请人： Billie M. York ,  Evan P. Kyba

    发明人： Billie M. York ,  Evan P. Kyba

    IPC分类号： C07C219/24 ,  C07C233/41 ,  C07C233/62 ,  A61K31/22 ,  A61K31/24 ,  C07C69/03 ,  C07C69/757

    CPC分类号： C07C233/41 ,  C07C219/24 ,  C07C233/62 ,  C07C2102/10

    摘要： Compounds having beta-2 adrenergic agonist activity and the use of these compounds in controlling intraocular pressure are disclosed. The compounds are believed to be useful in controlling intraocular pressure by increasing the outflow of aqueous humor. The compounds are considered to be less likely to cause cardiovascular side effects and various other side effects associated with stimulation of beta-1 receptors, relative to epinephrine.

    摘要翻译： 公开了具有β-2肾上腺素能激动剂活性的化合物和这些化合物在控制眼压中的用途。 据信这些化合物可用于通过增加房水的流出来控制眼内压。 认为这些化合物相对于肾上腺素不太可能引起与β-1受体的刺激相关的心血管副作用和各种其它副作用。

    Sub-tenon drug delivery
    2.
    发明授权
    Sub-tenon drug delivery 有权
    子腱药物递送

    公开(公告)号：US06413245B1

    公开(公告)日：2002-07-02

    申请号：US09677656

    申请日：2000-10-04

    申请人： Yoseph Yaacobi ,  Abbot F. Clark ,  David C. Dahlin ,  Craig B. Struble ,  David Allen Marsh ,  Billie M. York

    发明人： Yoseph Yaacobi ,  Abbot F. Clark ,  David C. Dahlin ,  Craig B. Struble ,  David Allen Marsh ,  Billie M. York

    IPC分类号： A61M2500

    CPC分类号： A61F9/0017 ,  A61F2250/0067

    摘要： Disclosed is a method and apparatus for delivering a drug formulation to a human eye. The method includes the steps of inserting the apparatus below the Tenon's capsule and above the sclera at a point posterior to the limbus of the eye and injecting the drug formulation to form a drug depot on an outer surface of the sclera. The apparatus includes a cannula having a distal portion, a proximal portion, and a bend separating the distal portion and the proximal portion. The distal portion has a radius of curvature substantially equal to a radius of curvature of the globe of the eye. A tangent of the distal portion at the bend is disposed at an angle no more than about 56 degrees with respect to the proximal portion.

    摘要翻译： 公开了用于将药物制剂递送至人眼的方法和装置。 该方法包括以下步骤：将装置插入Tenon's胶囊下方并在巩膜上方的眼睛边缘后方注射药物制剂以在巩膜的外表面上形成药物贮库。 该装置包括具有远侧部分，近端部分和分离远侧部分和近端部分的弯曲部的套管。 远端部分的曲率半径基本上等于眼睛球体的曲率半径。 弯曲处的远侧部分的切线相对于近端部分以不超过约56度的角度设置。

    Use of TGF-.beta.3, to prevent or retard fistula closure following glaucoma filtration surgery
    4.
    发明授权
    Use of TGF-.beta.3, to prevent or retard fistula closure following glaucoma filtration surgery 失效
    使用TGF-β3，预防或阻止青光眼过滤手术后的瘘闭合

    公开(公告)号：US5449671A

    公开(公告)日：1995-09-12

    申请号：US129962

    申请日：1993-09-29

    申请人： Jon C. Nixon ,  Billie M. York

    发明人： Jon C. Nixon ,  Billie M. York

    IPC分类号： A61K38/18 ,  A61K38/00

    CPC分类号： A61K38/1841

    摘要： The intraocular use of TGF-.beta..sub.3 in connection with glaucoma filtration surgery is described. A composition containing TGF-.beta..sub.3 is applied to the surgical site to suppress the production and/or alter the composition of extracellular matrix synthesized by fibroblasts at the surgical site, and thereby reduce the formation of scar tissue and consequent impairment of the outflow of aqueous humor through a fistula created during the surgery.

    摘要翻译： 描述了与青光眼滤过手术相关的TGF-β3的眼内使用。 将包含TGF-β3的组合物应用于手术部位以抑制在手术部位由成纤维细胞合成的细胞外基质的产生和/或改变组成，从而减少瘢痕组织的形成，从而导致水分流出的损伤 手术中产生的瘘管幽默。

    Use of TGF-.beta..sub.3 to reduce the formation of scar tissue in response to corneal trauma
    6.
    发明授权
    Use of TGF-.beta..sub.3 to reduce the formation of scar tissue in response to corneal trauma 失效
    使用TGF-β3来减少瘢痕组织对角膜创伤的反应

    公开(公告)号：US5411940A

    公开(公告)日：1995-05-02

    申请号：US128460

    申请日：1993-09-29

    申请人： Jon C. Nixon ,  Billie M. York

    发明人： Jon C. Nixon ,  Billie M. York

    IPC分类号： A61K38/18 ,  A61K38/00 ,  A61K38/27

    CPC分类号： A61K38/1841

    摘要： The use of TGF-.beta..sub.3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-.beta..sub.3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-.beta..sub.3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.

    摘要翻译： 描述了使用TGF-β3来减少由眼睛角膜创伤引起的瘢痕组织的形成。 本发明特别涉及使用TGF-β3来减少与涉及角膜的眼科手术相关的瘢痕组织的形成，例如角膜的激光照射。 将包含TGF-β3的组合物应用于创伤部位，以改变由成纤维细胞合成的细胞外基质的生成和组成，从而减少瘢痕组织的形成，从而减少视力。

    Compositions and methods for the treatment of the metabolically impaired and for improved compliance
    10.
    发明授权
    Compositions and methods for the treatment of the metabolically impaired and for improved compliance 失效
    用于治疗代谢障碍和改善依从性的组合物和方法

    公开(公告)号：US5521208A

    公开(公告)日：1996-05-28

    申请号：US99304

    申请日：1993-07-29

    申请人： Billie M. York

    发明人： Billie M. York

    IPC分类号： A61K31/415 ,  A61K31/40

    CPC分类号： A61K31/415 ,  Y10S514/866 ,  Y10S514/922

    摘要： Disclosed are novel compositions comprising mixtures useful to treat the metabolically impaired and to improve patient compliance. Included are non-racemic mixtures of certain chiral spirofluorenehydantoins. Methods of use to treat glucose toxicity and complications arising from diabetes mellitus are also disclosed.

    摘要翻译： 公开了包含可用于治疗代谢障碍并改善患者依从性的混合物的新型组合物。 包括某些手性螺芴壬内酯的非外消旋混合物。 还公开了用于治疗葡萄糖毒性的方法和由糖尿病引起的并发症。